aTyr Pharma
ATYR
33 hedge funds and large institutions have $12.1M invested in aTyr Pharma in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.43% less ownership
Funds ownership: 4.62% → 3.18% (-1.4%)
6% less funds holding
Funds holding: 35 → 33 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
76% less capital invested
Capital invested by funds: $51.3M → $12.1M (-$39.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$247K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$177K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$65.6K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$56.1K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$41.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.6M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.95M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$303K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$290K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$213K |
ATYR Hedge Fund Activity: Q2 2018 in Review
33 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2018, worth a combined $12.1M — down 76% from $51.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATYR and 8 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $247K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10.6M sold.
- 33 institutional investors held aTyr Pharma (ATYR) as of Q2 2018, down from 35 in Q1 2018.
- Funds reported $12.1M of aTyr Pharma stock for Q2 2018, down 76% quarter-over-quarter.
- 8 funds opened new aTyr Pharma positions in Q2 2018 and 10 closed out, a net change of -2 holders.
- The largest aTyr Pharma buyer in Q2 2018 was Renaissance Technologies, an estimated $247K added.
- The largest aTyr Pharma seller in Q2 2018 was EcoR1 Capital, an estimated $10.6M sold.
Based on aggregated 13F filings for Q2 2018.